|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,500,000 |
Market
Cap: |
2.01(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.65 - $65 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Amphastar Pharmaceuticals is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient (API) products. Co.'s reportable segments are: finished pharmaceutical products, which manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs; and API, which manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,000 |
384,322 |
579,546 |
794,601 |
Total Sell Value |
$42,551 |
$21,525,712 |
$32,066,990 |
$40,646,784 |
Total People Sold |
1 |
4 |
8 |
10 |
Total Sell Transactions |
2 |
10 |
25 |
62 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Luo Mary Z. |
COO, Chief Scientist, Chairman |
|
2017-03-17 |
4 |
D |
$13.75 |
$317,735 |
D/D |
(23,108) |
1,221,781 |
|
- |
|
Zhou Rong |
EVP, Production Center |
|
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
11,797 |
48,788 |
|
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
33,707 |
97,730 |
|
- |
|
Gerst Diane G. |
EVP, QA & Regulatory Affairs |
|
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,861 |
37,056 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
63,670 |
266,871 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist, Chairman |
|
2017-03-16 |
4 |
A |
$0.00 |
$0 |
I/I |
67,415 |
819,736 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist, Chairman |
|
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
156,554 |
1,244,889 |
|
- |
|
Petersen Floyd F. |
Director |
|
2017-01-03 |
4 |
AS |
$18.61 |
$7,444 |
D/D |
(400) |
58,717 |
|
- |
|
Gerst Diane G. |
EVP, QA & Regulatory Affairs |
|
2016-12-15 |
4 |
S |
$20.51 |
$60,287 |
D/D |
(2,940) |
26,195 |
|
- |
|
Zhou Rong |
EVP, Production Center |
|
2016-12-05 |
4 |
AS |
$20.70 |
$1,262 |
D/D |
(61) |
36,991 |
|
- |
|
Petersen Floyd F. |
Director |
|
2016-12-01 |
4 |
AS |
$20.26 |
$8,104 |
D/D |
(400) |
59,117 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2016-11-28 |
4 |
AS |
$20.47 |
$497,201 |
D/D |
(24,292) |
202,961 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2016-11-28 |
4 |
OE |
$10.93 |
$265,512 |
D/D |
24,292 |
227,253 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2016-11-25 |
4 |
AS |
$20.59 |
$42,057 |
D/D |
(2,043) |
202,961 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2016-11-25 |
4 |
OE |
$10.93 |
$22,330 |
D/D |
2,043 |
205,004 |
|
- |
|
Lee Howard |
Director |
|
2016-11-15 |
4 |
S |
$20.76 |
$373,510 |
D/D |
(17,994) |
114,527 |
|
- |
|
Lee Howard |
Director |
|
2016-11-15 |
4 |
OE |
$14.23 |
$256,055 |
D/D |
17,994 |
132,521 |
|
- |
|
Lee Howard |
Director |
|
2016-11-14 |
4 |
S |
$20.56 |
$411,170 |
D/D |
(20,000) |
114,527 |
|
- |
|
Lee Howard |
Director |
|
2016-11-14 |
4 |
OE |
$14.23 |
$284,600 |
D/D |
20,000 |
134,527 |
|
- |
|
Prins Richard K |
Director |
|
2016-11-11 |
4 |
S |
$20.06 |
$160,501 |
D/D |
(8,000) |
23,000 |
|
- |
|
Prins Richard K |
Director |
|
2016-11-11 |
4 |
OE |
$10.77 |
$53,850 |
D/D |
5,000 |
31,000 |
|
- |
|
Petersen Floyd F. |
Director |
|
2016-11-01 |
4 |
AS |
$18.09 |
$7,236 |
D/D |
(400) |
59,517 |
|
- |
|
Petersen Floyd F. |
Director |
|
2016-10-03 |
4 |
AS |
$18.75 |
$7,500 |
D/D |
(400) |
59,917 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2016-09-26 |
4 |
AS |
$19.50 |
$1,111,268 |
D/D |
(56,996) |
202,961 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2016-09-26 |
4 |
OE |
$10.93 |
$622,966 |
D/D |
56,996 |
259,957 |
|
- |
|
956 Records found
|
|
Page 29 of 39 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|